- Home
- FGEN vs IPSC Comparison
FGEN vs IPSC Comparison
Compare FGEN & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- IPSC
- Stock Information
- Founded
- FGEN 1993
- IPSC 2019
- Country
- FGEN United States
- IPSC United States
- Employees
- FGEN N/A
- IPSC N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- FGEN Health Care
- IPSC Health Care
- Exchange
- FGEN Nasdaq
- IPSC Nasdaq
- Market Cap
- FGEN 45.0M
- IPSC 43.2M
- IPO Year
- FGEN 2014
- IPSC 2021
- Fundamental
- Price
- FGEN $11.16
- IPSC $0.56
- Analyst Decision
- FGEN Strong Buy
- IPSC Strong Buy
- Analyst Count
- FGEN 2
- IPSC 5
- Target Price
- FGEN $146.50
- IPSC $3.33
- AVG Volume (30 Days)
- FGEN 30.7K
- IPSC 486.6K
- Earning Date
- FGEN 11-11-2025
- IPSC 11-04-2025
- Dividend Yield
- FGEN N/A
- IPSC N/A
- EPS Growth
- FGEN N/A
- IPSC N/A
- EPS
- FGEN N/A
- IPSC N/A
- Revenue
- FGEN $7,346,000.00
- IPSC $114,128,000.00
- Revenue This Year
- FGEN N/A
- IPSC $1,589.94
- Revenue Next Year
- FGEN N/A
- IPSC N/A
- P/E Ratio
- FGEN N/A
- IPSC N/A
- Revenue Growth
- FGEN N/A
- IPSC 5491.77
- 52 Week Low
- FGEN $4.50
- IPSC $0.34
- 52 Week High
- FGEN $21.94
- IPSC $1.83
- Technical
- Relative Strength Index (RSI)
- FGEN 46.07
- IPSC 60.86
- Support Level
- FGEN $11.36
- IPSC $0.48
- Resistance Level
- FGEN $12.13
- IPSC $0.51
- Average True Range (ATR)
- FGEN 0.54
- IPSC 0.03
- MACD
- FGEN -0.20
- IPSC 0.01
- Stochastic Oscillator
- FGEN 8.97
- IPSC 67.79
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.